Cargando…

Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study

BACKGROUND: Cardiovascular disease (CVD) is associated with a greater frailty risk, but it remains unknown if pathways that contribute to CVD are associated with the frailty risk. Thus, we aimed to investigate whether elevations in high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Yu, Li, Dongze, Yu, Jing, Liu, Yi, Li, Fanghui, Li, Wentao, Zhang, Qin, Gao, Yongli, Zhang, Wei, Zeng, Zhi, Zeng, Rui, Liao, Xiaoyang, Zhao, Qian, Wan, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006603/
https://www.ncbi.nlm.nih.gov/pubmed/35413794
http://dx.doi.org/10.1186/s12877-022-02974-z
_version_ 1784686700353552384
author Jia, Yu
Li, Dongze
Yu, Jing
Liu, Yi
Li, Fanghui
Li, Wentao
Zhang, Qin
Gao, Yongli
Zhang, Wei
Zeng, Zhi
Zeng, Rui
Liao, Xiaoyang
Zhao, Qian
Wan, Zhi
author_facet Jia, Yu
Li, Dongze
Yu, Jing
Liu, Yi
Li, Fanghui
Li, Wentao
Zhang, Qin
Gao, Yongli
Zhang, Wei
Zeng, Zhi
Zeng, Rui
Liao, Xiaoyang
Zhao, Qian
Wan, Zhi
author_sort Jia, Yu
collection PubMed
description BACKGROUND: Cardiovascular disease (CVD) is associated with a greater frailty risk, but it remains unknown if pathways that contribute to CVD are associated with the frailty risk. Thus, we aimed to investigate whether elevations in high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for those without known CVD at baseline are associated with a higher frailty risk. METHODS: This study used data from the Atherosclerosis Risk in Communities study. Cardiac biomarkers were measured from stored plasma samples collected at Visit 2 (1991–1993). Frailty was recorded at Visit 5 (2011–2013). Cox regression models were used to determine the association of cardiac biomarkers with frailty risk. RESULTS: Overall, 360/5199 (6.9%) participants aged 55.1 ± 5.1 years developed frailty during a median follow-up of 21.7 years. The incidence of frailty was significantly higher in participants with hs-cTnT ≥14 ng/L (vs. < 14 ng/L: 17.9% vs. 6.7%) or NT-proBNP ≥300 pg/ml (vs. < 300 pg/ml: 19.7% vs. 6.8%) (all P < 0.001). Comparing higher vs. lower cut-off levels of either hs-cTnT (14 ng/l) or NT-proBNP (300 pg/ml) demonstrated a greater than two-fold higher frailty risk, with hazard ratios (HRs) of 2.13 (95% confidence interval (CI): 1.130–4.01, P = 0.020) and 2.61 (95% CI: 1.28–5.33, P = 0.008), respectively. Individuals with both elevated hs-cTnT and NT-proBNP had a higher frailty risk than those without it (HR: 4.15; 95% CI: 1.50–11.48, P = 0.006). CONCLUSIONS: High hs-cTnT and NT-proBNP levels are strongly associated with incident frailty in the community-dwelling population without known CVD. Subclinical cardiac damage (hs-cTnT) and/or wall strain (NT-proBNP) may be the key pathway of CVD patients developing frailty. Detection of hs-cTnT and NT-proBNP may help for early screening of high-risk frailty and providing individualised intervention. TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005131. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-02974-z.
format Online
Article
Text
id pubmed-9006603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90066032022-04-14 Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study Jia, Yu Li, Dongze Yu, Jing Liu, Yi Li, Fanghui Li, Wentao Zhang, Qin Gao, Yongli Zhang, Wei Zeng, Zhi Zeng, Rui Liao, Xiaoyang Zhao, Qian Wan, Zhi BMC Geriatr Research BACKGROUND: Cardiovascular disease (CVD) is associated with a greater frailty risk, but it remains unknown if pathways that contribute to CVD are associated with the frailty risk. Thus, we aimed to investigate whether elevations in high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for those without known CVD at baseline are associated with a higher frailty risk. METHODS: This study used data from the Atherosclerosis Risk in Communities study. Cardiac biomarkers were measured from stored plasma samples collected at Visit 2 (1991–1993). Frailty was recorded at Visit 5 (2011–2013). Cox regression models were used to determine the association of cardiac biomarkers with frailty risk. RESULTS: Overall, 360/5199 (6.9%) participants aged 55.1 ± 5.1 years developed frailty during a median follow-up of 21.7 years. The incidence of frailty was significantly higher in participants with hs-cTnT ≥14 ng/L (vs. < 14 ng/L: 17.9% vs. 6.7%) or NT-proBNP ≥300 pg/ml (vs. < 300 pg/ml: 19.7% vs. 6.8%) (all P < 0.001). Comparing higher vs. lower cut-off levels of either hs-cTnT (14 ng/l) or NT-proBNP (300 pg/ml) demonstrated a greater than two-fold higher frailty risk, with hazard ratios (HRs) of 2.13 (95% confidence interval (CI): 1.130–4.01, P = 0.020) and 2.61 (95% CI: 1.28–5.33, P = 0.008), respectively. Individuals with both elevated hs-cTnT and NT-proBNP had a higher frailty risk than those without it (HR: 4.15; 95% CI: 1.50–11.48, P = 0.006). CONCLUSIONS: High hs-cTnT and NT-proBNP levels are strongly associated with incident frailty in the community-dwelling population without known CVD. Subclinical cardiac damage (hs-cTnT) and/or wall strain (NT-proBNP) may be the key pathway of CVD patients developing frailty. Detection of hs-cTnT and NT-proBNP may help for early screening of high-risk frailty and providing individualised intervention. TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005131. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-02974-z. BioMed Central 2022-04-12 /pmc/articles/PMC9006603/ /pubmed/35413794 http://dx.doi.org/10.1186/s12877-022-02974-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jia, Yu
Li, Dongze
Yu, Jing
Liu, Yi
Li, Fanghui
Li, Wentao
Zhang, Qin
Gao, Yongli
Zhang, Wei
Zeng, Zhi
Zeng, Rui
Liao, Xiaoyang
Zhao, Qian
Wan, Zhi
Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
title Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
title_full Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
title_fullStr Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
title_full_unstemmed Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
title_short Subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
title_sort subclinical cardiovascular disease and frailty risk: the atherosclerosis risk in communities study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006603/
https://www.ncbi.nlm.nih.gov/pubmed/35413794
http://dx.doi.org/10.1186/s12877-022-02974-z
work_keys_str_mv AT jiayu subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT lidongze subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT yujing subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT liuyi subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT lifanghui subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT liwentao subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT zhangqin subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT gaoyongli subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT zhangwei subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT zengzhi subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT zengrui subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT liaoxiaoyang subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT zhaoqian subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy
AT wanzhi subclinicalcardiovasculardiseaseandfrailtyrisktheatherosclerosisriskincommunitiesstudy